Payment for immunosuppression after organ transplantation

Bertram L. Kasiske, David Cohen, Michael R. Lucey, John F. Neylan

Research output: Contribution to journalReview articlepeer-review

84 Scopus citations


Dramatic improvements in organ transplantation have meant that a growing number of patients must take expensive immunosuppressive medications for the rest of their lives. Currently, Medicare covers most transplantation procedures in the United States, but ends coverage for outpatient immunosuppressive medications after 36 months. Evidence suggests that at least some patients have reduced immunosuppression and their transplant fail because they cannot afford these medication costs. In the years since the advent of effective immunosuppressive therapy, the US Congress has struggled with this issue, and in 1999 temporarily extended medication coverage for eligible patients (based on age and disability) by 8 months. However, a more permanent solution is needed. We advocate that Medicare should cover the cost of all immunosuppressive therapy for all solid organ transplant recipients who cannot afford to pay. A number of potentially cost-effective approaches could be taken, but, in any case, something must be done to ensure that transplants do not fail because recipients cannot pay for immunosuppression.

Original languageEnglish (US)
Pages (from-to)2445-2450
Number of pages6
Issue number18
StatePublished - May 10 2000
Externally publishedYes


Dive into the research topics of 'Payment for immunosuppression after organ transplantation'. Together they form a unique fingerprint.

Cite this